Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $51.00 price target on the stock. HC Wainwright's price target indicates a potential upside of 241.37% from the company's current price.

A number of other equities analysts have also recently issued reports on SNDX. UBS Group began coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price objective on the stock. Barclays boosted their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, August 15th. The Goldman Sachs Group boosted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Bank of America boosted their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Finally, StockNews.com cut shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $37.64.

Syndax Pharmaceuticals Trading Down 4.0 %

Shares of SNDX stock traded down $0.62 during mid-day trading on Tuesday, reaching $14.94. The stock had a trading volume of 1,867,821 shares, compared to its average volume of 1,184,414. The stock's 50-day moving average price is $18.22 and its two-hundred day moving average price is $19.62. Syndax Pharmaceuticals has a 52-week low of $14.57 and a 52-week high of $25.34. The firm has a market capitalization of $1.28 billion, a PE ratio of -4.29 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.16 million. During the same quarter in the previous year, the firm posted ($0.73) EPS. On average, equities research analysts forecast that Syndax Pharmaceuticals will post -2.39 earnings per share for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth approximately $27,000. Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $30,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth approximately $33,000. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth approximately $49,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after buying an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).